Athena Fountain, NP
Family · Savannah, GANPI 1356560577
Payments from drug & device makers
Across 502 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- GSK$2K
- AstraZeneca$957
- Axsome Therapeutics, Inc.$835
- Regeneron Healthcare Solutions, Inc.$667
- Harmony Biosciences LLC$624
- plus $4K from 28 others
What the payments were for
- Travel & lodging$1,0689%
- Food & beverage$10,10790%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 35 | $2,564 |
| GSK | 128 | $1,885 |
| AstraZeneca | 45 | $957 |
| Axsome Therapeutics, Inc. | 48 | $835 |
| Regeneron Healthcare Solutions, Inc. | 35 | $667 |
| Harmony Biosciences LLC | 28 | $624 |
| Jazz Pharmaceuticals Inc. | 27 | $485 |
| Mylan Specialty L.p. | 20 | $404 |
| Sanofi | 15 | $386 |
| Actelion Pharmaceuticals US, Inc. | 16 | $319 |
| Mallinckrodt Hospital Products Inc. | 13 | $251 |
| United Therapeutics Corporation | 10 | $225 |
| Merck | 11 | $203 |
| Insmed, Inc. | 8 | $189 |
| Verona Pharma, Inc. | 7 | $166 |
| Amgen | 8 | $163 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $143 |
| Boehringer Ingelheim | 6 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $114 |
| Inari Medical, Inc. | 1 | $69 |
| Vifor Pharma, Inc. | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Viatris Specialty LLC | 3 | $50 |
| Lilly USA, LLC | 2 | $44 |
| Fisher & Paykel Healthcare Inc | 2 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Eisai Inc. | 3 | $41 |
| Noctrix Health, Inc. | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Optinose US, Inc. | 2 | $30 |
| Boston Scientific | 1 | $28 |
| Grifols USA, LLC | 1 | $22 |
| Electromed, Inc. | 3 | $19 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,267 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $98,353 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 74 | $56,728 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $38,945 |
| Spiriva RespimatTiotropium Bromide | 27 | $20,492 |
| Modafinil | 41 | $9,726 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $8,823 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $8,419 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,639 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 311 | $7,557 |
| DayvigoLemborexant | 18 | $5,940 |
| BelsomraSuvorexant | 13 | $5,715 |
| Fluticasone Propionate | 185 | $3,183 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $1,993 |
| Armodafinil | 39 | $1,609 |
| Trazodone Hcl | 220 | $1,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,885 | $145,717203 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $957 | $64,36697 claims |
| Boehringer IngelheimSpiriva Respimat | $115 | $20,49227 claims |
| Eisai Inc.Dayvigo | $41 | $5,94018 claims |
| MerckBelsomra | $203 | $5,71513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Savannah
- Kaitlyn BuchananSavannah$24K
- Shelby CallowaySavannah$16K
- Erin RedmondSavannah$15K
- Caroline SauersSavannah$14K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.